1. Preface
     1.1. Market Definition and Scope
     1.2. Market Segmentation
     1.3. Key Research Objectives
     1.4. Research Highlights

2. Assumptions and Research Methodology

3. Executive Summary: Global Adult Malignant Glioma Therapeutics Market

4. Market Overview
     4.1. Introduction
            4.1.1. Market Definition
            4.1.2. Industry Evolution / Developments
     4.2. Overview
     4.3. Market Dynamics by region
            4.3.1. Drivers
            4.3.2. Restraints
            4.3.3. Opportunities
     4.4. Global Adult Malignant Glioma Therapeutics Market Analysis and Forecast, 2016–2026
            4.4.1. Market Revenue Projections (US$ Mn)
     4.5. Porter’s Five Force Analysis, by Region

5. Market Outlook
     5.1. Adult Malignant Glioma Disease Overview
            5.1.1 Glioblastoma Multiforme
            5.1.2. Anaplastic Astrocytoma
            5.1.3. Anaplastic Oligodendroglioma
            5.1.4. Anaplastic Oligoastrocytoma
            5.1.5. Others
     5.2. Pipeline Analysis
            5.2.1. Phase III & IV Drugs Market Forecast
            5.2.1. Phase I & II Drug Candidates Comparative Analysis
     5.3. Porter’s Five Force Analysis, by Region
     5.4. Epidemiology of Glioma
            5.4.1. Prevalence, by Country
            5.4.2. Prevalence, by Type of Glioma
            5.4.3. Incidence Rate, by Country
            5.4.4. Incidence Rate, by Type of Glioma
     5.5. Disease Burden by Key Regions / Country
            5.5.1. North America
            5.5.2. Europe
            5.5.3. Asia Pacific
            5.5.4. Rest of the World
     5.6. SWOT Analysis, by Key Therapies
     5.7. Regulatory Scenario, by Key Region / Country
     5.8. Reimbursement Scenario, by Key Region / Country
     5.9. Imaging Technologies Landscape in Glioma Analysis
     5.10. Key Market Trends, by Region

6. Global Adult Malignant Glioma Therapeutics Market Analysis and Forecast, by Type
     6.1. Introduction & Definition
     6.2. Key Findings / Developments
     6.3. Global Adult Malignant Glioma Therapeutics Market Value Forecast, by Type, 2016– 2026
            6.3.1. Glioblastoma Multiforme
            6.3.2. Anaplastic Astrocytoma
            6.3.3. Anaplastic Oligodendroglioma
            6.3.4. Anaplastic Oligoastrocytoma
            6.3.5. Others
     6.4. Global Adult Malignant Glioma Therapeutics Market Attractiveness, by Type

7. Global Adult Malignant Glioma Therapeutics Market Analysis and Forecast, by Therapy
     7.1. Introduction & Definition
     7.2. Key Findings / Developments
     7.3. Global Adult Malignant Glioma Therapeutics Market Value Forecast, by Therapy, 2016–2026
            7.3.1. Chemotherapy
                     7.3.1.1. Temozolomide
                     7.3.1.2. Bevacizumab
                     7.3.1.3. Carmustine
                     7.3.1.4. Others
            7.3.2. Targeted Drug Therapy
                     7.3.2.1. Epidermal Growth Factor Receptor (EGFR) Inhibitors
                     7.3.2.2. Other Monoclonal Antibodies
                     7.3.2.3. Others
            7.3.3. Radiation Therapy
     7.4. Global Adult Malignant Glioma Therapeutics Market Attractiveness, by Therapy

8. Global Adult Malignant Glioma Therapeutics Market Analysis and Forecast, by Region
     8.1. Key Findings
     8.2. Global Adult Malignant Glioma Therapeutics Market Value Forecast, by Region
            8.2.1. North America
            8.2.2. Europe
            8.2.3. Asia Pacific
            8.2.4. Latin America
            8.2.5. Middle East & Africa
     8.3. Market Attractiveness, by Region

9. North America Adult Malignant Glioma Therapeutics Market Analysis and Forecast
     9.1. Introduction
            9.1.1. Key Findings
     9.2. North America Adult Malignant Glioma Therapeutics Market Value Forecast, by Type, 2016–2026
            9.2.1. Glioblastoma Multiforme
            9.2.2. Anaplastic Astrocytoma
            9.2.3. Anaplastic Oligodendroglioma
            9.2.4. Anaplastic Oligoastrocytoma
            9.2.5. Others
     9.3. North America Adult Malignant Glioma Therapeutics Market Value Forecast, by Therapy, 2016–2026
            9.3.1. Chemotherapy
                     9.3.1.1. Temozolomide
                     9.3.1.2. Bevacizumab
                     9.3.1.3. Carmustine
                     9.3.1.4. Others
            9.3.2. Targeted Drug Therapy
                     9.3.2.1. Epidermal Growth Factor Receptor (EGFR) Inhibitors
                     9.3.2.2. Other Monoclonal Antibodies
                     9.3.2.3. Others
            9.3.3. Radiation Therapy
     9.4. North America Adult Malignant Glioma Therapeutics Market Value Forecast, by Country, 2016–2026
            9.4.1. U.S.
            9.4.2. Canada
     9.5. Market Attractiveness Analysis
            9.5.1. By Type
            9.5.2. By Therapy
            9.5.3. By Country

10. Europe Adult Malignant Glioma Therapeutics Market Analysis and Forecast
     10.1. Introduction
            10.1.1. Key Findings
     10.2. Europe Adult Malignant Glioma Therapeutics Market Value Forecast, by Type, 2016–2026
            10.2.1. Glioblastoma Multiforme
            10.2.2. Anaplastic Astrocytoma
            10.2.3. Anaplastic Oligodendroglioma
            10.2.4. Anaplastic Oligoastrocytoma
            10.2.5. Others
     10.3. Europe Adult Malignant Glioma Therapeutics Market Value Forecast, by Therapy, 2016–2026
            10.3.1. Chemotherapy
                     10.3.1.1. Temozolomide
                     10.3.1.2. Bevacizumab
                     10.3.1.3. Carmustine
                     10.3.1.4. Others
            10.3.2. Targeted Drug Therapy
                     10.3.2.1. Epidermal Growth Factor Receptor (EGFR) Inhibitors
                     10.3.2.2. Other Monoclonal Antibodies
                     10.3.2.3. Others
            10.3.3. Radiation Therapy
     10.4. Europe Adult Malignant Glioma Therapeutics Market Value Forecast, by Country/Sub-region, 2016–2026
            10.4.1. Germany
            10.4.2. U.K.
            10.4.3. France
            10.4.4. Spain
            10.4.5. Italy
            10.4.6. Rest of Europe
     10.5. Europe Adult Malignant Glioma Therapeutics Market Attractiveness Analysis
            10.5.1. By Type
            10.5.2. By Therapy
            10.5.3. By Country/Sub-region

11. Asia Pacific Adult Malignant Glioma Therapeutics Market Analysis and Forecast
     11.1.Introduction
            11.1.1. Key Findings
     11.2. Asia Pacific Adult Malignant Glioma Therapeutics Market Value Forecast, by Type, 2016–2026
            11.2.1. Glioblastoma Multiforme
            11.2.2. Anaplastic Astrocytoma
            11.2.3. Anaplastic Oligodendroglioma
            11.2.4. Anaplastic Oligoastrocytoma
            11.2.5. Others
     11.3. Asia Pacific Adult Malignant Glioma Therapeutics Market Value Forecast, by Therapy, 2016–2026
            11.3.1. Chemotherapy
                     11.3.1.1. Temozolomide
                     11.3.1.2. Bevacizumab
                     11.3.1.3. Carmustine
                     11.3.1.4. Others
            11.3.2. Targeted Drug Therapy
                     11.3.2.1. Epidermal Growth Factor Receptor (EGFR) Inhibitors
                     11.3.2.2. Other Monoclonal Antibodies
                     11.3.2.3. Others
            11.3.3. Radiation Therapy
     11.4. Asia Pacific Adult Malignant Glioma Therapeutics Market Value Forecast, by Country/Sub-region, 2016–2026
            11.4.1. China
            11.4.2. Japan
            11.4.3. India
            11.4.4. Rest of Asia Pacific
     11.5. Asia Pacific Adult Malignant Glioma Therapeutics Market Attractiveness Analysis
            11.5.1. By Type
            11.5.2. By Therapy
            11.5.3. By Country/Sub-region

12. Latin America Adult Malignant Glioma Therapeutics Market Analysis and Forecast
     12.1.Introduction
            12.1.1. Key Findings
     12.2. Latin America Adult Malignant Glioma Therapeutics Market Value Forecast, by Type, 2016–2026
            12.2.1. Glioblastoma Multiforme
            12.2.2. Anaplastic Astrocytoma
            12.2.3. Anaplastic Oligodendroglioma
            12.2.4. Anaplastic Oligoastrocytoma
            12.2.5. Others
     12.3. Asia Pacific Adult Malignant Glioma Therapeutics Market Value Forecast, by Therapy, 2016–2026
            12.3.1. Chemotherapy
                     12.3.1.1. Temozolomide
                     12.3.1.2. Bevacizumab
                     12.3.1.3. Carmustine
                     12.3.1.4. Others
            12.3.2. Targeted Drug Therapy
                     12.3.2.1. Epidermal Growth Factor Receptor (EGFR) Inhibitors
                     12.3.2.2. Other Monoclonal Antibodies
                     12.3.2.3. Others
            12.3.3. Radiation Therapy
     12.4. Asia Pacific Adult Malignant Glioma Therapeutics Market Value Forecast, by Country/Sub-region, 2016–2026
            12.4.1. Brazil
            12.4.2. Mexico
            12.4.3. Rest of Latin America
     12.5. Asia Pacific Adult Malignant Glioma Therapeutics Market Attractiveness Analysis
            12.5.1. By Type
            12.5.2. By Therapy
            12.5.3. By Country/Sub-region

13. Middle East & Africa Adult Malignant Glioma Therapeutics Market Analysis and Forecast
     13.1.Introduction
            13.1.1. Key Findings
     13.2. MEA Adult Malignant Glioma Therapeutics Market Value Forecast, by Type, 2016–2026
            13.2.1. Glioblastoma Multiforme
            13.2.2. Anaplastic Astrocytoma
            13.2.3. Anaplastic Oligodendroglioma
            13.2.4. Anaplastic Oligoastrocytoma
            13.2.5. Others
     13.3. MEA Adult Malignant Glioma Therapeutics Market Value Forecast, by Therapy, 2016–2026
            13.3.1. Chemotherapy
                     13.3.1.1. Temozolomide
                     13.3.1.2. Bevacizumab
                     13.3.1.3. Carmustine
                     13.3.1.4. Others
            13.3.2. Targeted Drug Therapy
                     13.3.2.1. Epidermal Growth Factor Receptor (EGFR) Inhibitors
                     13.3.2.2. Other Monoclonal Antibodies
                     13.3.2.3. Others
            13.3.3. Radiation Therapy
     13.4. MEA Adult Malignant Glioma Therapeutics Market Value Forecast, by Country/Sub-region, 2016–2026
            13.4.1. GCC Countries
            13.4.2. South Africa
            13.4.3. Rest of Middle East & Africa
     13.5. MEA Adult Malignant Glioma Therapeutics Market Attractiveness Analysis
            13.5.1. By Type
            13.5.2. By Therapy
            13.5.3. By Country/Sub-region

14. Competition Landscape
     14.1.Market Player - Competition Matrix (By Tier and Size of companies)
     14.2.Market Share Analysis, by Company (2017)
     14.3.Market Footprint Analysis
     14.4. Competitive Business Strategies
     14.5. Company Profiles
            14.5.1. Merck & Co., Inc.
                     14.5.1.1. Company Overview (HQ, Business Segments, Employee Strength)
                     14.5.1.2. Product Portfolio
                     14.5.1.3. SWOT Analysis
                     14.5.1.4. Strategic Overview
                     14.5.1.5. Financial Overview
            14.5.2. F. Hoffmann-La Roche Ltd.
                     14.5.2.1. Company Overview (HQ, Business Segments, Employee Strength)
                     14.5.2.2. Product Portfolio
                     14.5.2.3. SWOT Analysis
                     14.5.2.4. Strategic Overview
                     14.5.2.5. Financial Overview
            14.5.3. Arbor Pharmaceuticals
                     14.5.3.1. Company Overview (HQ, Business Segments, Employee Strength)
                     14.5.3.2. Product Portfolio
                     14.5.3.3. SWOT Analysis
                     14.5.3.4. Strategic Overview
                     14.5.3.5. Financial Overview
            14.5.4. Pfizer, Inc.
                     14.5.4.1. Company Overview (HQ, Business Segments, Employee Strength)
                     14.5.4.2. Product Portfolio
                     14.5.4.3. SWOT Analysis
                     14.5.4.4. Strategic Overview
                     14.5.4.5. Financial Overview
            14.5.5. AbbVie, Inc.
                     14.5.5.1. Company Overview (HQ, Business Segments, Employee Strength)
                     14.5.5.2. Product Portfolio
                     14.5.5.3. SWOT Analysis
                     14.5.5.4. Strategic Overview
                     14.5.5.5. Financial Overview
            14.5.6. Amgen, Inc.
                     14.5.6.1. Company Overview (HQ, Business Segments, Employee Strength)
                     14.5.6.2. Product Portfolio
                     14.5.6.3. SWOT Analysis
                     14.5.6.4. Strategic Overview
                     14.5.6.5. Financial Overview
            14.5.7. Bristol-Myers Squibb Company
                     14.5.7.1. Company Overview (HQ, Business Segments, Employee Strength)
                     14.5.7.2. Product Portfolio
                     14.5.7.3. SWOT Analysis
                     14.5.7.4. Strategic Overview
                     14.5.7.5. Financial Overview
            14.5.8. Sun Pharmaceuticals Ltd.
                     14.5.8.1. Company Overview (HQ, Business Segments, Employee Strength)
                     14.5.8.2. Product Portfolio
                     14.5.8.3. SWOT Analysis
                     14.5.8.4. Strategic Overview
                     14.5.8.5. Financial Overview
            14.5.9. Teva Pharmaceutical Industries Limited
                     14.5.9.1. Company Overview (HQ, Business Segments, Employee Strength)
                     14.5.9.2. Product Portfolio
                     14.5.9.3. SWOT Analysis
                     14.5.9.4. Strategic Overview
                     14.5.9.5. Financial Overview
            14.5.10. Emcure Pharmaceuticals Limited
                     14.5.10.1. Company Overview (HQ, Business Segments, Employee Strength)
                     14.5.10.2. Product Portfolio
                     14.5.10.3. SWOT Analysis
                     14.5.10.4. Strategic Overview
                     14.5.10.5. Financial Overview

List of Tables

Table 01: Signatures and Clinical Features of Glioblastoma (GBM) Subtypes
Table 02: Disease Burden, by Key Region/Country (1/2)
Table 03: Disease Burden, by Key Region/Country (2/2)
Table 04: Comparative Analysis of Orphan Drug Policies
Table 05: Global Adult Malignant Glioma Therapeutics Market Value (US$ Mn) Forecast, by Type, 2016–2026
Table 06: Global Adult Malignant Glioma Therapeutics Market Value (US$ Mn) Forecast, by Therapy, 2016–2026
Table 07: Global Adult Malignant Glioma Therapeutics Market Value (US$ Mn) Forecast, by Chemotherapy, 2016–2026
Table 08: Global Adult Malignant Glioma Therapeutics Market Value (US$ Mn) Forecast, by Targeted Drug Therapy, 2016–2026
Table 09: Global Adult Malignant Glioma Therapeutics Market Value (US$ Mn) Forecast, by Region, 2016–2026
Table 10: North America Adult Malignant Glioma Therapeutics Market Value (US$ Mn) Forecast, by Country, 2016–2026
Table 11: North America Adult Malignant Glioma Therapeutics Market Value (US$ Mn) Forecast, by Type, 2016–2026
Table 12: North America Adult Malignant Glioma Therapeutics Market Value (US$ Mn) Forecast, by Therapy, 2016–2026
Table 13: North America Adult Malignant Glioma Therapeutics Market Value (US$ Mn) Forecast, by Chemotherapy, 2016–2026
Table 14: North America Adult Malignant Glioma Therapeutics Market Value (US$ Mn) Forecast, by Targeted Drug Therapy, 2016–2026
Table 15: Europe Adult Malignant Glioma Therapeutics Market Value (US$ Mn) Forecast, by Country/Sub-region, 2016–2026
Table 16: Europe Adult Malignant Glioma Therapeutics Market Value (US$ Mn) Forecast, by Type, 2016–2026
Table 17: Europe Adult Malignant Glioma Therapeutics Market Value (US$ Mn) Forecast, by Therapy, 2016–2026
Table 18: Europe Adult Malignant Glioma Therapeutics Market Value (US$ Mn) Forecast, by Chemotherapy, 2016–2026
Table 19: Europe Adult Malignant Glioma Therapeutics Market Value (US$ Mn) Forecast, by Targeted Drug Therapy, 2016–2026
Table 20: Asia Pacific Adult Malignant Glioma Therapeutics Market Value (US$ Mn) Forecast, by Country/Sub-region, 2016–2026
Table 21: Asia Pacific Adult Malignant Glioma Therapeutics Market Value (US$ Mn) Forecast, by Type, 2016–2026
Table 22: Asia Pacific Adult Malignant Glioma Therapeutics Market Value (US$ Mn) Forecast, by Therapy, 2016–2026
Table 23: Asia Pacific Adult Malignant Glioma Therapeutics Market Value (US$ Mn) Forecast, by Chemotherapy, 2016–2026
Table 24: Asia Pacific Adult Malignant Glioma Therapeutics Market Value (US$ Mn) Forecast, by Targeted Drug Therapy, 2016–2026
Table 25: Latin America Adult Malignant Glioma Therapeutics Market Value (US$ Mn) Forecast, by Country/Sub-region, 2016–2026
Table 26: Latin America Adult Malignant Glioma Therapeutics Market Value (US$ Mn) Forecast, by Type, 2016–2026
Table 27: Latin America Adult Malignant Glioma Therapeutics Market Value (US$ Mn) Forecast, by Therapy, 2016–2026
Table 28: Latin America Adult Malignant Glioma Therapeutics Market Value (US$ Mn) Forecast, by Chemotherapy, 2016–2026
Table 29: Latin America Adult Malignant Glioma Therapeutics Market Value (US$ Mn) Forecast, by Targeted Drug Therapy, 2016–2026
Table 30: Middle East & Africa Adult Malignant Glioma Therapeutics Market Value (US$ Mn) Forecast, by Country/Sub-region, 2016–2026
Table 31: Middle East & Africa Adult Malignant Glioma Therapeutics Market Value (US$ Mn) Forecast, by Type, 2016–2026
Table 32: Middle East & Africa Adult Malignant Glioma Therapeutics Market Value (US$ Mn) Forecast, by Therapy, 2016–2026
Table 33: Middle East & Africa Adult Malignant Glioma Therapeutics Market Value (US$ Mn) Forecast, by Chemotherapy, 2016–2026
Table 34: Middle East & Africa Adult Malignant Glioma Therapeutics Market Value (US$ Mn) Forecast, by Targeted Drug Therapy, 2016–2026

List of Figures

Figure 01: Global Adult Malignant Glioma Therapeutics Market Value (US$ Mn) Forecast, 2016–2026
Figure 02: Global Adult Malignant Glioma Therapeutics Market Value Share (%), by Type (2017)
Figure 03: Global Adult Malignant Glioma Therapeutics Market Value Share (%), by Therapy (2017)
Figure 04: Global Adult Malignant Glioma Therapeutics Market Value Share (%), by Region (2017)
Figure 05: Overall Survival Time of Glioblastoma Patients, by Therapy
Figure 06: Overall Survival Time of Glioblastoma Patients, by Age Group
Figure 07: Glioblastoma Patients Relative Survival Rates
Figure 08: Overall Incidence Rate of Glioma %
Figure 09: Regulatory Approval Process - U.S.
Figure 10: Regulatory Approval Process - Europe
Figure 11: Regulatory Approval Process - Japan
Figure 12: Global Adult Malignant Glioma Therapeutics Market Trends, by Region
Figure 13: Global Adult Malignant Glioma Therapeutics Market Value Share (%), by Type, 2017 and 2026
Figure 14: Global Adult Malignant Glioma Therapeutics Market Attractiveness, by Type, 2018–2026
Figure 15: Global Adult Malignant Glioma Therapeutics Market Revenue (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, by Glioblastoma Multiforme, 2016–2026
Figure 16: Global Adult Malignant Glioma Therapeutics Market Revenue (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, by Anaplastic Astrocytoma, 2016–2026
Figure 17: Global Adult Malignant Glioma Therapeutics Market Revenue (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, by Anaplastic Oligodendroglioma, 2016–2026
Figure 18: Global Adult Malignant Glioma Therapeutics Market Revenue (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, by Anaplastic Oligoastrocytoma, 2016–2026
Figure 19: Global Adult Malignant Glioma Therapeutics Market Revenue (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, by Others, 2016–2026
Figure 20: Global Adult Malignant Glioma Therapeutics Market Value Share (%), by Therapy, 2017 and 2026
Figure 21: Global Adult Malignant Glioma Therapeutics Market Attractiveness, by Therapy, 2018–2026
Figure 22: Global Adult Malignant Glioma Therapeutics Market Revenue (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, by Chemotherapy, 2016–2026
Figure 23: Global Adult Malignant Glioma Therapeutics Market Revenue (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, by Targeted Therapy, 2016–2026
Figure 24: Global Adult Malignant Glioma Therapeutics Market Revenue (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, by Radiation Therapy, 2016–2026
Figure 25: Global Adult Malignant Glioma Therapeutics Market Value Share (%), by Region, 2017 and 2026
Figure 26: Global Adult Malignant Glioma Therapeutics Market Attractiveness, by Region, 2018–2026
Figure 27: North America Adult Malignant Glioma Therapeutics Market Revenue (US$ Mn) and Y-o-Y Growth (%) Forecast, 2016–2026
Figure 28: North America Adult Malignant Glioma Therapeutics Market Value Share (%), by Country, 2017 and 2026
Figure 29: North America Adult Malignant Glioma Therapeutics Market Attractiveness, by Country, 2018– 2026
Figure 30: North America Adult Malignant Glioma Therapeutics Market Value Share (%), by Type, 2017 and 2026
Figure 31: North America Adult Malignant Glioma Therapeutics Market Attractiveness, by Type, 2018–2026
Figure 32: North America Adult Malignant Glioma Therapeutics Market Value Share (%), by Therapy, 2017 and 2026
Figure 33: North America Adult Malignant Glioma Therapeutics Market Attractiveness, by Therapy, 2018– 2026
Figure 34: Europe Adult Malignant Glioma Therapeutics Market Revenue (US$ Mn) and Y-o-Y Growth (%) Forecast, 2016–2026
Figure 35: Europe Adult Malignant Glioma Therapeutics Market Value Share (%), by Country/Sub-region, 2017 and 2026
Figure 36: Europe Adult Malignant Glioma Therapeutics Market Attractiveness, by Country/Sub-region, 2018–2026
Figure 37: Europe Adult Malignant Glioma Therapeutics Market Value Share (%), by Type, 2017 and 2026
Figure 38: Europe Adult Malignant Glioma Therapeutics Market Attractiveness, by Type, 2018–2026
Figure 39: Europe Adult Malignant Glioma Therapeutics Market Value Share (%), by Therapy, 2017 and 2026
Figure 40: Europe Adult Malignant Glioma Therapeutics Market Attractiveness, by Therapy, 2018–2026
Figure 41: Asia Pacific Adult Malignant Glioma Therapeutics Market Revenue (US$ Mn) and Y-o-Y Growth (%) Forecast, 2016–2026
Figure 42: Asia Pacific Adult Malignant Glioma Therapeutics Market Value Share (%), by Country/Sub- region, 2017 and 2026
Figure 43: Asia Pacific Adult Malignant Glioma Therapeutics Market Attractiveness, by Country/Sub-region, 2018–2026
Figure 44: Asia Pacific Adult Malignant Glioma Therapeutics Market Value Share (%), by Type 2017 and 2026
Figure 45: Asia Pacific Adult Malignant Glioma Therapeutics Market Attractiveness, by Type, 2018–2026
Figure 46: Asia Pacific Adult Malignant Glioma Therapeutics Market Value Share (%), by Therapy 2017 and 2026
Figure 47: Asia Pacific Adult Malignant Glioma Therapeutics Market Attractiveness, by Therapy 2018–2026
Figure 48: Latin America Adult Malignant Glioma Therapeutics Market Revenue (US$ Mn) and Y-o-Y Growth (%) Forecast, 2016–2026
Figure 49: Latin America Adult Malignant Glioma Therapeutics Market Value Share (%), by Country/Sub- region, 2017 and 2026
Figure 50: Latin America Adult Malignant Glioma Therapeutics Market Attractiveness, by Country/Sub- region, 2018–2026
Figure 51: Latin America Adult Malignant Glioma Therapeutics Market Value Share (%), by Type, 2017 and 2026
Figure 52: Latin America Adult Malignant Glioma Therapeutics Market Attractiveness, by Type, 2018–2026
Figure 53: Latin America Adult Malignant Glioma Therapeutics Market Value Share (%), by Therapy, 2017 and 2026
Figure 54: Latin America Adult Malignant Glioma Therapeutics Market Attractiveness, by Therapy, 2018– 2026
Figure 55 Middle East & Africa Adult Malignant Glioma Therapeutics Market Revenue (US$ Mn) and Y-o-Y Growth (%) Forecast, 2016–2026
Figure 56: Middle East & Africa Adult Malignant Glioma Therapeutics Market Value Share (%), by Country/Sub-region, 2017 and 2026
Figure 57: Middle East & Africa Adult Malignant Glioma Therapeutics Market Attractiveness, by Country/Sub-region, 2018–2026
Figure 58: Middle East & Africa Adult Malignant Glioma Therapeutics Market Value Share (%), by Type, 2017 and 2026
Figure 59: Middle East & Africa Adult Malignant Glioma Therapeutics Market Attractiveness, by Type, 2018– 2026
Figure 60: Middle East & Africa Adult Malignant Glioma Therapeutics Market Value Share (%), by Therapy, 2017 and 2026
Figure 61: Middle East & Africa Adult Malignant Glioma Therapeutics Market Attractiveness, by Therapy, 2018–2026
Figure 62: Global Adult Malignant Glioma Therapeutics Market Share, by Company, 2017
Figure 63: AbbVie, Inc. Revenue (US$ Bn) and Y-o-Y Growth (%), 2014–2017
Figure 64: AbbVie, Inc. Breakdown of Net Sales, by Region, 2017
Figure 65: AbbVie, Inc. Breakdown of Net Sales, by Drug, 2017
Figure 66: AbbVie, Inc. Research and Development Cost (US$ Mn), 2015–2017
Figure 67: Merck & Co., Inc. Revenue (US$ Mn) & Y-o-Y Growth (%), 2015–2017
Figure 68: Merck & Co., Inc. Breakdown of Net Sales, by Region, 2017
Figure 69: Merck & Co., Inc. Breakdown of Net Sales, by Business Segment, 2017
Figure 70: Merck & Co., Inc. Research & Development Cost, 2015–2017 (US$ Bn)
Figure 71: Pfizer Inc. Revenue (US$ Mn) and Y-o-Y Growth (%), 2014–2017
Figure 72: Pfizer Inc. R&D Expenses (US$ Mn), 2014–2017
Figure 73: F. Hoffmann-La Roche Ltd Revenue (US$ Mn) & Y-o-Y Growth (%), 2014–2017
Figure 74: F. Hoffmann-La Roche Ltd Breakdown of Net Sales, by Region, 2017
Figure 75: F. Hoffmann-La Roche Ltd Breakdown of Net Sales, by Business Segment, 2017
Figure 76: F. Hoffmann-La Roche Ltd Research & Development Cost, 2015–2017 (US$ Mn)
Figure 77: Bristol-Myers Squibb Company Revenue (US$ Bn) & Y-o-Y Growth (%), 2014–2017
Figure 78: Bristol-Myers Squibb Company Breakdown of Net Sales (%), by Region, 2017
Figure 79: Bristol-Myers Squibb Company Breakdown of Net Sales, by Product Segment, 2017
Figure 80: Bristol-Myers Squibb Company Research & Development Cost, 2015–2017 (US$ Mn)
Figure 81: Amgen, Inc. Revenue (US$ Bn) and Y-o-Y Growth (%), 2014–2017
Figure 82: Amgen, Inc. Breakdown of Net Sales, by Region, 2017
Figure 83: Amgen, Inc. Breakdown of Net Sales, by Type of Sale, 2017
Figure 84: Amgen, Inc. Research and Development Cost (US$ Mn), 2015–2017
Figure 85: Sun Pharmaceuticals Ltd. Revenue (US$ Mn) and Y-o-Y Growth (%), 2013–2016
Figure 86: Sun Pharmaceuticals Ltd. Breakdown of Net Sales, by Region, 2017
Figure 87: Sun Pharmaceuticals Ltd. Breakdown of Net Sales, by Product Segment, 2017
Figure 88: Sun Pharmaceuticals Ltd. Research & Development Cost (US$ Mn), 2015–2017
Figure 89: Teva Pharmaceutical Industries Limited Revenue (US$ Bn) and Y-o-Y Growth (%), 2014–2017
Figure 90: Teva Pharmaceutical Industries Limited Breakdown of Net Sales, by Region, 2017
Figure 91: Teva Pharmaceutical Industries Limited Breakdown of Net Sales, by Business Segment, 2017
Figure 92: Teva Pharmaceutical Industries Limited Research and Development Cost (US$ Mn), 2015–2017

Custom Market Research Services

TMR offers custom market research services that help clients to get information on their business scenario required where syndicated solutions are not enough.

REQUEST CUSTOMIZATION

Adult Malignant Glioma Therapeutics Market

Buy Now